Axsome settles SUNOSI patent litigation; generic entry delayed to 2040

Axsome Therapeutics, Inc.

Alkem can sell generic SUNOSI on/after March 1, 2040 (no pediatric exclusivity) or September 1, 2040 (if granted), subject to FDA approval.
Settlement resolves Alkem's ANDA patent litigation in District of New Jersey; similar litigation with another party remains pending.
Agreement submitted to FTC and DOJ for review as required by law.
No financial terms disclosed in the settlement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.